Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm

Area of Science:

• Oncology
• Pharmacology
• Surgical Risk Management

Background:

• Tamoxifen is a crucial adjuvant endocrine therapy for pre-menopausal, estrogen receptor-positive breast cancer.
• A known side effect of Tamoxifen is an increased risk of venous thrombo-embolism (VTE).
• This VTE risk is significantly elevated in patients undergoing high-risk surgeries with prolonged immobilization.

Purpose of the Study:

• To propose a working algorithm for managing Tamoxifen treatment cessation around surgical procedures.
• To provide evidence-based guidance for surgeons on safe treatment stoppage durations.
• To mitigate peri-operative VTE risk in breast cancer patients undergoing surgery.

Main Methods:

• Literature review of VTE risk factors, including patient age, surgical procedure type, and Tamoxifen pharmacokinetics.
• Development of a risk assessment algorithm for patient stratification.
• Consideration of operative risks, drug pharmacokinetics, and chemotherapy interactions.

Main Results:

• The proposed algorithm aims to identify appropriate patient groups for Tamoxifen interruption.
• It suggests safe durations for treatment stoppage in the peri-operative period.
• The guidelines integrate VTE, surgical, and oncological risk factors.

Conclusions:

• Implementing structured, evidence-based guidelines can aid surgeons in peri-operative Tamoxifen management.
• The proposed algorithm offers a systematic approach to balance VTE risk reduction and cancer treatment continuity.
• Standardized guidelines are needed to address the current variability in clinical practice.